Pricing Log in Create free account

BioLineRx Ltd. (BLRX) vs IN8bio, Inc. (INAB)

BioLineRx Ltd. and IN8bio, Inc. are both Biotechnology companies. BioLineRx Ltd. and IN8bio, Inc. are of similar size ($8.8M and $8.2M). IN8bio, Inc. has the higher net margin (0.00% vs −502.1%) and the lower return on invested capital (−2,948.6% vs −74.3%). Across the 14 metrics below, BioLineRx Ltd. leads on 8 and IN8bio, Inc. on 6.

Valuation

Metric BLRX INAB Biotechnology median
P/E n/m n/m 10.26
P/S 5.65 n/m 9.18
P/B 0.47 0.89 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m 0.08 0.65
EV/Sales 1.06 n/m 8.98
Earnings yield (90.47%) (255.95%) (34.89%)
Free cash flow yield (137.86%) (89.47%) (24.52%)

Profitability

Metric BLRX INAB Biotechnology median
Gross margin 80.03% 0.00% 65.16%
Operating margin (874.28%) 0.00% 0.00%
Net margin (502.08%) 0.00% 0.00%
Free cash flow margin (776.29%) 0.00% 0.00%
Return on equity (38.10%) (111.11%) (50.12%)
Return on assets (18.21%) (90.80%) (45.60%)
Return on invested capital (74.28%) (2,948.56%) 0.00%

Growth

Metric BLRX INAB Biotechnology median
Revenue growth (TTM) (91.93%) — 6.26%
EPS growth (last fiscal year) 93.72% 74.06% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BLRX INAB Biotechnology median
Debt to equity 0.40 0.00 0.00
Current ratio 1.20 8.21 4.89
Net debt to EBITDA 1.22 1.56 1.01

Dividend

Metric BLRX INAB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BLRX INAB Biotechnology median
Market cap 8.80m 8.19m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack